Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-904P is a processed pseudogene derived from U6 small nuclear RNA, a core component of the spliceosome involved in pre-mRNA splicing in eukaryotes[3]. Pseudogenes like RNU6-904P are typically generated via retrotransposition or duplication of parental snRNA genes, resulting in defective, non-expressing copies scattered in the genome[2][7]. While U6 snRNA itself is critical for splicing, RNU6-904P does not produce a functional RNA or protein and has not been reported to play a role in cellular biology or disease. Most pseudogenes are considered genomic fossils, although some pseudogenes contribute to gene regulation via RNA-mediated mechanisms or chromatin modification, but there is no current evidence of such activity for RNU6-904P[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 904, pseudogene (RNU6-904P).